Chirag Bakhai

Chirag Bakhai

Auto-generated profile, based on publicly available information

Chirag Bakhai

NHS Bedfordshire Luton and Milton Keynes Integrated Care Board Luton UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
EBEmma Barron
Emma Barron
SSStephen J. Sharp
Stephen J. Sharp
KKKamlesh Khunti
Kamlesh Khunti
CBChirag Bakhai
Chirag Bakhai
NWNicholas J. Wareham
Nicholas J. Wareham
JVJonathan Valabhji
Jonathan Valabhji
To assess the effects of non-diabetic hyperglycaemia (NDH, also known as pre-diabetes), including the impact of the NHS Diabetes Prevention Programme (NHS DPP), on COVID-19-related mortality during the pandemic. This study included all 61,438,225 individuals registered with General Practices in England and alive on 1st March 2020. We assessed COVID-19-related mortality in the 2,290,280(3.7 %) individuals with diagnosed NDH between March 2020 and February 2022 compared to those without diagnosed NDH or diabetes using Cox regression to adjust for demographic factors and cardiovascular comorbidities. Individuals with diagnosed NDH were further sub-categorised based on their contact with the NHS DPP (N = 376,590). Analyses were stratified by age (years) (<50, 50-69 and ≥ 70). There were 158,070 COVID-19 deaths; 17,280(11 %) for people with diagnosed NDH. The adjusted hazard ratio (HR) was 0.95(0.93-0.96),p < 0.001 for those with diagnosed NDH compared to those without diagnosed diabetes or NDH. By age (years), HRs were, 2.53(2.23-2.88),p < 0.001 for < 50, 1.29(1.24-1.35),p < 0.001 for 50-69 and 0.87(0.85-0.89),p < 0.001 for ≥ 70. NHS DPP attendance was associated with lower COVID-19 mortality with a dose-response relationship with engagement. Younger people with diagnosed NDH were at higher relative risk of COVID-19 mortality. Attendance at the NHS DPP was associated with significantly lower COVID-19-related mortality.

1 July 2025 in Health and Social Care Delivery Research
Verified
Journal Article
Open access
LELouisa Ells
Louisa Ells
Tamara BrownTamara Brown
Tamara Brown
JMJamie Matu
Jamie Matu
KCKen Clare
Ken Clare
SRSimon Rowlands
Simon Rowlands
CBChirag Bakhai
Chirag Bakhai
Background: National Health Service England piloted a low-calorie diet programme, delivered through total diet replacement and behaviour change support via 1 : 1, group or digital delivery, to improve type 2 diabetes in adults with excess weight. Aim: To coproduce a qualitative and economic evaluation of the National Health Service low-calorie diet pilot, integrated with National Health Service data to provide an enhanced understanding of the long-term cost-effectiveness, implementation, equity and transferability across broad and diverse populations. Research questions: What are the theoretical principles, behaviour change components, content and mode of delivery of the programme, and is it delivered with fidelity to National Health Service specifications? What are the service provider, user and National Health Service staff experiences of the programme? Do sociodemographics influence programme access, uptake, compliance and success? What aspects of the service work and what do not work, for whom, in what context and why? Can the programme be improved to enhance patient experience and address inequities? What are the programme delivery costs, and policy implications for wide-spread adoption? Methods: A mixed-methods study underpinned by a realist-informed approach was delivered across five work packages, involving: semistructured interviews with service users (n = 67), National Health Service staff (n = 55), service providers (n = 9); 13 service provider focus groups; and service user surveys (n = 719). Findings were triangulated with clinical data from the National Health Service England’s first cohort analysis (n = 7540). Results: Fifty-five per cent of service users who started total diet replacement completed the programme and lost an average of 10.3 kg; 32% of those with data available to measure remission achieved it. Examination of programme mobilisation identified barriers around referral equality and the impact of COVID-19, while effective cross-stakeholder working and communication were key facilitators. Service delivery and fidelity assessments identified a drift in implementation fidelity, alongside variation in the behaviour change content across providers. Perceived barriers to programme uptake and engagement aligned across service providers and users, resulting in key learning on: the importance of person-centred care, service user support needs, improvements to total diet replacement and the social and cultural impact of the programme. Early National Health Service quantitative analyses suggest some socioeconomic variation in programme uptake, completion and outcomes. Insights from the evaluation and National Health Service data were combined to develop the programme theory and underpinning context, mechanisms and outcomes. These were used to develop a list of recommendations to improve the cultural competency of programme delivery, total diet replacement delivery, peer support and address psychological support needs. Cost-effectiveness analyses using short-term follow-up data indicated there is potential for the programme to be cost-effective, but not cost saving. Conclusions: The National Health Service low-calorie diet can provide a clinically effective and potentially cost-effective programme to support weight loss and glycaemic control in adults with type 2 diabetes. However, this evaluation identified areas for improvement in referral equity, uptake and completion, and fidelity of delivery, which have informed the development of the programme, which has now been rolled out nationally. Ongoing programme monitoring and long-term follow-up are now required. Future work and limitations: The real-world setting limited some data collection and analysis. Future work will focus on the analysis of long-term clinical and cost-effectiveness, and addressing inequalities. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme as award number NIHR132075.

5 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
PMPatrick Muller
Patrick Muller
JWJonathan Wray
Jonathan Wray
MRMuksitur Rahman
Muksitur Rahman
JHJames Hawkins
James Hawkins
CBChirag Bakhai
Chirag Bakhai
LOLesley Owen
Lesley Owen
Aims: An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication. Materials and Methods: Observational cohort study using Clinical Practice Research Data Link records linked to hospital admissions. Presence of a current prescription for an SGLT2 inhibitor was evaluated in people with T2DM on 1 st September 2023, stratified by CVD category (CVD only; HF only; both; high CVD risk; low CVD risk) and chronic kidney disease status, and by age, gender, ethnicity, deprivation, and T2DM duration. Adjusted associations between patient characteristics and uptake were evaluated using logistic regression. Results: In the cohort of 587,826 people with T2DM, the percentage with a current prescription was 19.5% for people with CVD, 29.4% for people with HF, 30.5% for people with both CVD and HF, and 19.9% and 20.2% respectively for people at high and low CVD risk. In age-stratified analyses uptake was higher in people with more comorbidities. In adjusted models, uptake was lower in people aged >60, women, Black people, and people living in areas of higher deprivation. Conclusions: Whilst prescribing of SGLT2 inhibitors continues to rise in England, recent trends indicate an opportunity remains to increase uptake. Action is necessary to address inequalities by ethnicity and deprivation, and lower uptake for people with T2DM and CVD without HF.

10 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LOLesley Owen
Lesley Owen
CBChirag Bakhai
Chirag Bakhai
JWJonathan Wray
Jonathan Wray
MRMuksit Rahman
Muksit Rahman
JHJames Hawkins
James Hawkins
PMPatrick Muller
Patrick Muller
Background: Health inequalities remain a major public health challenge in England, with people living in more deprived areas experiencing poorer outcomes. Although SGLT2 inhibitors (SGLT2i) are clinically and cost-effective for type 2 diabetes mellitus (T2DM) and related cardiovascular and renal conditions, little is known about how their health benefits are distributed across deprivation groups. We examined the distribution of health benefits associated with SGLT2i across deprivation and clinical subgroups, and the implications for health inequalities.Methods: We used data from a 2023 cross-sectional analysis of the Clinical Practice Research Datalink (CPRD), linked to Hospital Episodes Statistics (HES) and small-area deprivation data in England. T2DM prevalence and selected comorbidities and SGLT2i uptake were estimated across deprivation quintiles. A distributional cost-effectiveness analysis was used to estimate total and net health benefits (QALYs) and opportunity costs. Scenario analyses examined increased uptake and alternative distributions of opportunity costs.Findings: T2DM and associated comorbidities were more prevalent in more deprived areas across all subgroups. SGLT2i uptake varied modestly by deprivation but more substantially across clinical subgroups. SGLT2i generated positive net health benefits across all groups, with the largest gains accruing to more deprived populations, reflecting disease burden and baseline risk. Increasing uptake increased health gains, with similar distributional patterns across deprivation groups.Interpretation: SGLT2i generate substantial net health benefits across all deprivation groups, with the greatest gains in more deprived populations. Improving uptake represents an important opportunity to improve population health while reducing health inequalities.

4 August 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
PMPatrick Muller
Patrick Muller
JWJonathan Wray
Jonathan Wray
MRMuksitur Rahman
Muksitur Rahman
JHJames Hawkins
James Hawkins
CBChirag Bakhai
Chirag Bakhai
LOLesley Owen
Lesley Owen
Aims: An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication. Materials and Methods: Observational cohort study using Clinical Practise Research Data Link records linked to hospital admissions. Presence of a current prescription for an SGLT2 inhibitor was evaluated in people with T2DM on 1 September 2023, stratified by CVD category (CVD only; HF only; both; high CVD risk; low CVD risk) and chronic kidney disease status, and by age, gender, ethnicity, deprivation and T2DM duration. Adjusted associations between patient characteristics and uptake were evaluated using logistic regression. Results: In the cohort of 587 826 people with T2DM, the percentage with a current prescription was 19.5% for people with CVD, 29.4% for people with HF, 30.5% for people with both CVD and HF, and 19.9% and 20.2% respectively for people at high and low CVD risk. In age‐stratified analyses, uptake was higher in people with more comorbidities. In adjusted models, uptake was lower in people aged > 60, women, Black people and people living in areas of higher deprivation. Conclusions: Whilst prescribing of SGLT2 inhibitors continues to rise in England, recent trends indicate an opportunity remains to increase uptake. Action is necessary to address inequalities by ethnicity and deprivation, and lower uptake for people with T2DM and CVD without HF.